Early worsening heart failure in patients admitted with acute heart failure – a new outcome measure associated with long‐term prognosis?

A major limitation in acute heart failure (AHF) research has been the lack of an outcome measure paralleling re‐infarction in acute coronary syndromes. The aim of the present study was to assess the time course, prognostic factors and outcome of early worsening heart failure (WHF) in patients admitted for AHF to a community hospital. All AHF admissions between December 2003 and March 2004 in a regional medical center were recorded. Patients were followed through admission and for 6 months after discharge. Early WHF was defined as WHF occurring during the initial 7 days from admission. Study endpoints were cardiovascular mortality and WHF (defined as worsening or persistent signs or symptoms of AHF requiring rescue therapy or hospital readmission). Early WHF rate was 29% and was associated with markers of AHF severity on presentation (higher troponin I, lower oxygen saturation, need for mechanical ventilation, intravascular diuretics and inotropes). Early WHF was a powerful predictor of death during 6 months of follow up, with an age‐adjusted hazard ratio of 3.3 (95% confidence interval 1.7–6.3). Early WHF is a common adverse event in patients admitted with AHF, and is associated with AHF severity and excessive 6‐month mortality. WHF should be considered as a clinically important endpoint in AHF studies.

[1]  C. O'connor,et al.  The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. , 2008, Journal of cardiac failure.

[2]  J. Cleland,et al.  Clinical trials update from the American College of Cardiology 2008: Carisma, Trends, meta‐analysis of Cox‐2 studies, Hat, on‐Target, Hyvet, Accomplish, Momentum, Protect, Horizon‐hf and Reverse , 2008, European journal of heart failure.

[3]  M. Gheorghiade,et al.  A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach. , 2008, European heart journal.

[4]  K. Furie,et al.  Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2008, Circulation.

[5]  C. O'connor,et al.  Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. , 2007, JAMA.

[6]  J. Cleland,et al.  Clinical trials update from the European Society of Cardiology heart failure meeting: TNT subgroup analysis, darbepoetin alfa, FERRIC‐HF and KW‐3902 , 2006, European journal of heart failure.

[7]  N. Freemantle,et al.  Clinical trials update from the American Heart Association: REPAIR‐AMI, ASTAMI, JELIS, MEGA, REVIVE‐II, SURVIVE, and PROACTIVE , 2006, European journal of heart failure.

[8]  C. O'connor,et al.  Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). , 2005, American heart journal.

[9]  Dario Gregori,et al.  Temporal trends in survival and hospitalizations in outpatients with chronic systolic heart failure in 1995 and 1999. , 2005, Journal of cardiac failure.

[10]  Eliot Corday,et al.  Overview of Acutely Decompensated Congestive Heart Failure (ADHF): A Report from the ADHERE Registry , 2005, Heart Failure Reviews.

[11]  C. Richter,et al.  The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure , 2004, European journal of heart failure.

[12]  C. O'connor,et al.  Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. , 2004, American heart journal.

[13]  M. Gheorghiade,et al.  Hospitalization for worsening chronic heart failure. , 2004, Italian heart journal : official journal of the Italian Federation of Cardiology.

[14]  P. Austin,et al.  Trends in heart failure outcomes and pharmacotherapy: 1992 to 2000. , 2004, The American journal of medicine.

[15]  Peter C Austin,et al.  Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. , 2003, JAMA.

[16]  B. Brendorp,et al.  Long-term survival in patients hospitalized with congestive heart failure: relation to preserved and reduced left ventricular systolic function. , 2003, European heart journal.

[17]  P. Varadarajan,et al.  Prognosis of congestive heart failure in patients with normal versus reduced ejection fractions: results from a cohort of 2,258 hospitalized patients. , 2003, Journal of cardiac failure.

[18]  N Freemantle,et al.  The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. , 2003, European heart journal.

[19]  D. DeMets,et al.  Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study , 2002, Circulation.

[20]  James B. Young Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: A randomized controlled trial , 2002 .

[21]  M. Cuffe Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. , 2002, JAMA.

[22]  M C Oz,et al.  Long-term use of a left ventricular assist device for end-stage heart failure. , 2001, The New England journal of medicine.

[23]  A. Takeshita,et al.  Mortality and readmission of hospitalized patients with congestive heart failure and preserved versus depressed systolic function. , 2001, The American journal of cardiology.

[24]  F. Zannad,et al.  Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL Study. Epidémiologie de l'Insuffisance Cardiaque Avancée en Lorraine. , 1999, Journal of the American College of Cardiology.